publication venue for
- Shift from Widespread to Tailored Antifungal Prophylaxis in Lymphoma Patients Treated with CD19 CAR T Cell Therapy: Results from a Large Retrospective Cohort. 2024
- Total Body Irradiation and Fludarabine with Post-Transplantation Cyclophosphamide for Mismatched Related or Unrelated Donor Hematopoietic Cell Transplantation.. 30:1013.e1-1013.e12. 2024
- In Pursuit of Optimal Outcomes: A Framework for Quality Standards in Immune Effector Cell Therapy.. 30:942-954. 2024
- Subsequent Malignancies After CD19-Targeted Chimeric Antigen Receptor T Cells in Patients With Lymphoma.. 30:990-1000. 2024
- Consolidation with First and Second Allogeneic Transplants in Adults with Relapsed/Refractory B-ALL Following Response to CD19CAR T Cell Therapy.. 30:788.e1-788.e9. 2024
- Transplantation-Associated Altered Mentation and Encephalopathy: A New Classification for Acute Neurocognitive Changes Associated with Hematopoietic Cell Transplantation from the ASTCT Committee on Practice Guidelines.. 30:646-662. 2024
- Preconditioning Frailty Phenotype Influences Survival and Relapse for Older Allogeneic Transplantation Recipients.. 30:415.e1-415.e16. 2024
- Tocilizumab for Cytokine Release Syndrome Management After Haploidentical Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis.. 29:515.e1-515.e7. 2023
- The Transplant Ecosystem: A New Concept to Improve Access and Outcomes for Older Allogeneic Hematopoietic Cell Patients.. 29:632.e1-632.e10. 2023
- TP53 Mutations Are Associated with Increased Infections and Reduced Hematopoietic Cell Transplantation Rates in Myelodysplastic Syndrome and Acute Myeloid Leukemia.. 29:390.e1-390.e10. 2023
- Post-Transplantation Sinusoidal Obstruction Syndrome in Adult Patients with B Cell Acute Lymphoblastic Leukemia Treated with Pretransplantation Inotuzumab.. 29:314-320. 2023
- Bridging Radiation Rapidly and Effectively Cytoreduces High Risk Relapsed/Refractory Aggressive B-Cell Lymphomas Prior to Chimeric Antigen Receptor T-Cell Therapy.. 29:259.e1-259.e10. 2022
- A Phase I Trial of SYK Inhibition with Fostamatinib in the Prevention and Treatment of Chronic Graft-Versus-Host Disease.. 29:179.e1-179.e10. 2022
- Allogeneic Transplantation for Older Patients with Acute Myeloid Leukemia: The Dawn of a New Era.. 28:793-794. 2022
- Correlation of Engraftment and Time from Melphalan Administration to Stem Cell Infusion.. 29:36.e1-36.e5. 2022
- Frequently Asked Questions on Coronavirus Disease 2019 Vaccination for Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Recipients From the American Society for Transplantation and Cellular Therapy and the American Society of Hematology.. 29:10-18. 2022
- Health-Related Quality of Life Following Allogeneic Hematopoietic Cell Transplantation with Omidubicel versus Umbilical Cord Blood.. 29:52.e1-52.e9. 2022
- Revised Guidelines for Coronavirus Disease 19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients (August 2022).. 28:810-821. 2022
- Vitamin D Insufficiency and Clinical Outcomes with Chimeric Antigen Receptor T-Cell Therapy in Large B-cell Lymphoma.. 28:751.e1-751.e7. 2022
- Geriatric Assessment Reveals Actionable Impairments in Hematopoietic Stem Cell Transplantation Candidates Age 18 to 80 Years.. 28:498.e1-498.e9. 2022
- eHealth-Generated Patient Data in an Outpatient Setting after Hematopoietic Stem Cell Transplantation: A Scoping Review.. 28:463-471. 2022
- Change in Patients' Perceived Cognition Following Chimeric Antigen Receptor T-Cell Therapy for Lymphoma.. 28:401.e1-401.e7. 2022
- Total Marrow and Lymphoid Irradiation with Post-Transplant Cyclophosphamide for Patients with AML in Remission.. 28:368.e1-368.e7. 2022
- Change in Neurocognitive Performance Among Patients with Non-Hodgkin Lymphoma in the First Year after Chimeric Antigen Receptor T Cell Therapy.. 28:305.e1-305.e9. 2022
- Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review.. 28:294-302. 2022
- Patterns and Predictors of Functional Decline after Allogeneic Hematopoietic Cell Transplantation in Older Adults.. 28:309.e1-309.e9. 2022
- Reduction in the Prevalence of Thrombotic Events in Sickle Cell Disease after Allogeneic Hematopoietic Transplantation.. 28:277.e1-277.e6. 2022
- Home-Based Hematopoietic Cell Transplantation in the United States.. 28:207.e1-207.e8. 2022
- Longitudinal Patient Reported Outcomes with CAR-T Cell Therapy Versus Autologous and Allogeneic Stem Cell Transplant.. 28:473-482. 2022
- Hematopoietic Cell Transplantation is Feasible in Patients with Prior COVID-19 Infection.. 28:55.e1-55.e5. 2021
- Planned Granulocyte Colony-Stimulating Factor Adversely Impacts Survival after Allogeneic Hematopoietic Cell Transplantation Performed with Thymoglobulin for Myeloid Malignancy.. 27:993.e1-993.e8. 2021
- Female Sex Is Associated with Improved Long-Term Survival Following Allogeneic Hematopoietic Stem Cell Transplantation.. 27:784.e1-784.e7. 2021
- Relapse after Allogeneic Stem Cell Transplantation of Acute Myelogenous Leukemia and Myelodysplastic Syndrome and the Importance of Second Cellular Therapy.. 27:771.e1-771.e10. 2021
- Decreased Mortality in 1-Year Survivors of Umbilical Cord Blood Transplant vs. Matched Related or Matched Unrelated Donor Transplant in Patients with Hematologic Malignancies.. 27:669.e1-669.e8. 2021
- Breaking the Age Barrier: Physicians' Perceptions of Candidacy for Allogeneic Hematopoietic Cell Transplantation in Older Adults.. 27:617.e1-617.e7. 2021
- Cellular Therapy During COVID-19: Lessons Learned and Preparing for Subsequent Waves.. 27:438.e1-438.e6. 2021
- Chlorhexidine Gluconate Bathing Reduces the Incidence of Bloodstream Infections in Adults Undergoing Inpatient Hematopoietic Cell Transplantation.. 27:262.e1-262.e11. 2021
- Allogeneic Hematopoietic Cell Transplantation for Relapsed and Refractory Philadelphia Negative B Cell ALL in the Era of Novel Salvage Therapies.. 27:255.e1-255.e9. 2020
- Discharge Disposition Following Hematopoietic Cell Transplantation: Predicting the Need for Rehabilitation and Association with Survival.. 27:337.e1-337.e7. 2020
- Assessing the Feasibility of a Novel mHealth App in Hematopoietic Stem Cell Transplant Patients.. 27:181.e1-181.e9. 2020